On the recordSeptember 10, 2024
Mr. Speaker, I rise today to outline my concerns with H.R. 8333, the BIOSECURE Act, which I voted against last night. This bill, though well-intentioned, is poorly drafted and shows the deficit of proper process. The BIOSECURE Act would only apply to contracts subject to the Federal Acquisition Regulation System. That is the Department of Defense and the Department of Veterans Affairs. This means that while Medicare and commercial-plan beneficiaries could access the drugs comprehended by the BIOSECURE Act, veterans and servicemembers could be alienated from treatments and cures that are available to other Americans. This bifurcation is not only unfair, but it renders the disincentive to biotechs ineffective. This legislation also fails to provide due process so that Congress is not veering into potential bill of attainder challenges. In its form, the bill is not fit to function and makes no attempt to support a domestic CDMO or CRO industry. ____________________





